The study will include 10 adult patients with cystic fibrosis. The aim of the study is to evaluate whether Tobramycin 300 mg aerosol once-a-day for 28 days can reduce the bacterial load in the airways. Secondary end-point is the evaluation of variation in bacterial susceptibility during and at the end of study period.
Ten adult patients with cystic fibrosis will be enrolled in a stable phase and will received prophylaxis with aerosol of Tobramycin 300 mg once a day for 28 days.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
10
inhaled tobramycin 300 mg single dose OD for 28 days
IRCCS Ospedale Maggiore Policlinico via F. Sforza 35
Milan, Italy
Evaluation of bacterial load decrease
Bacterial load in sputum will be evaluated during and at the end of treatment
Time frame: day 7-9 vs day 1, day 14-16 vs day 7-9, day 28-30 vs day 14-26
Evaluation of inflammatory serum biomarker
Serum levels of biomarker (PCT) will be evaluated during and at the end of treatment
Time frame: day7-9 vs day 1, Day 14-16 vs day 7-9, Day 28-30 vs 14-16
Evaluation of serum biomarker
Evaluation of C-reactive protein levels during and at the end of treatment
Time frame: day7-9 vs day 1, Day 14-16 vs day 7-9, Day 28-30 vs 14-16
Evaluation of serum biomarker
Evaluation of KL6 levels during and at the end of treatment
Time frame: day7-9 vs day 1, Day 14-16 vs day 7-9, Day 28-30 vs 14-16
evaluation of serum biomarker
Evaluation of interleukin 6 during and at the end of treatment
Time frame: day7-9 vs day 1, Day 14-16 vs day 7-9, Day 28-30 vs 14-16
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.